title: [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
abstract: BACKGROUND
  In Germany, data on the quality of life (QoL) of patients with advanced prostate cancer (PCa) under therapy with gonadotropin-releasing hormone (GnRH) analogues are limited.
  
  
  OBJECTIVE
  Androgen deprivation (ADT) is a palliative therapy for patients with advanced PCa, which is given over long periods and usually continued in combination with other therapies even after progression of the disease. The present study aimed to assess prospectively (over 1 year) different aspects of patients' QoL therapy with triptorelin in daily practice.
  
  
  METHODS
  This prospective, noninterventional study at 129 centers in Germany included 608 patients with advanced PCa treated with triptorelin. Quality of life was assessed at baseline and after 6 and 12 months, using validated EORTC QLQ-C30 and QLQ-PR25 questionnaires. Predefined subgroup analyses were performed to assess the impact of demographics, anamnestic and clinical parameters on QoL.
  
  
  CONCLUSIONS
  The majority of patients with PCa under therapy with triptorelin showed generally stable global QoL over 1 year; approximately one-quarters of the patients had a clinically relevant improvement of their global QoL. In patients without previous PCa therapy and GnRH analogue treatment, significant improvements in global QoL were seen. At the same time, these patients also reported increased treatment-related symptoms. These data indicate that the perception of global QoL is not only influenced by subjective impairment through ADT-related side effects.
authors.affiliation: Praxisklinik Urologie Rhein Ruhr, Schulstraße 11, 45468, Mülheim an der Ruhr, Deutschland. a.eisenhardt@pur-r.de.
authors.forename: A
authors.initials: A
authors.lastname: Eisenhardt
authors.affiliation: Praxisklinik Urologie Rhein Ruhr, Schulstraße 11, 45468, Mülheim an der Ruhr, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Schneider
authors.affiliation: GKM Gesellschaft für Therapieforschung, München, Deutschland.
authors.forename: K
authors.initials: K
authors.lastname: Scheithe
authors.affiliation: Ipsen Pharma GmbH, Ettlingen, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Colling
authors.affiliation: Klinik für Urologie, Universitätsklinikum Aachen, Aachen, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D005858:Germany; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D011788:Quality of Life / Q000523:psychology*; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone
keywords: Adenocarcinoma; Gonadotropin-releasing hormone; Hormone therapy; Palliative care; Sexual dysfunction